SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to news of a proposed convertible notes offering, sparking discussions about dilution and future growth. The community is debating whether this is a bullish move to raise capital for expansion or a sign of overvaluation. Some investors remain optimistic, pointing to the company's shift towards AI cloud services and potential for significant revenue growth.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amidst community discussion around recent price declines, despite positive quarterly reports indicating revenue growth and increased user base. Some investors attribute the volatility to potential share lock-up expirations and market manipulation, while others see it as an opportunity to buy the dip. The conversation also includes comparisons to other fintech platforms and speculation on future performance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to high volume and after-hours price surges, sparking speculation about potential news or a significant catalyst. Community members are actively discussing the reasons behind the spike, with some pointing to the company's positioning in the AI and data center sectors as a key driver. There's also discussion around a recent capital raise and its implications for future growth and potential partnerships.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following an expanded joint development agreement with Murata to scale production of ceramic separators for its solid-state batteries, sparking bullish sentiment. The community is actively discussing the significance of this partnership for mass production and potential deals with major companies, while some anticipate a short squeeze. Overall, the focus remains on QuantumScape's progress toward commercializing its solid-state battery technology and the potential impact on the EV and broader energy storage market.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending due to significant price movement and heavy community discussion around its strategic shift towards crypto, specifically building a $100M TON treasury, which is generating both excitement and skepticism. Traders are actively discussing potential for a short squeeze, comparing it to other recent low-float runners, and speculating on upcoming news related to its crypto initiatives. The community's focus is on the stock's volatility and potential for rapid gains, balanced against concerns about dilution and the company's transition from biotechnology.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies Corp is trending due to growing excitement around its potential in quantum-safe cybersecurity, especially following news of key personnel joining the company. The community is actively discussing its undervalued status compared to other quantum computing stocks and its real-world applications. Chatter also highlights potential partnerships and the increasing need for quantum-resistant solutions in various sectors.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is experiencing significant volatility, fueled by speculative trading and a low float, leading to rapid price swings that have captured the attention of day traders. Community members are actively debating its potential for further gains, while others caution against a potential pump-and-dump scenario. The stock's performance is being compared to other recent high-flying, low-float stocks, driving interest and discussions around short squeezes.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending due to a $500 million common stock offering to fund certification and manufacturing, sparking discussions about dilution and buying opportunities. While some investors express concerns about revenue and market cap, others view this as a strategic move for long-term growth in the eVTOL sector. Community sentiment is mixed, with some hoping for a price dip to increase their positions.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending amid renewed interest in deep-sea mining, with the community actively discussing potential government partnerships and regulatory approvals that could act as catalysts. Bullish sentiment is fueled by the anticipation of a short squeeze and a potential breakout, as well as the company's long-term prospects in the critical minerals market.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy ($MSTR) is trending as Bitcoin's surge to new highs sparks both excitement and frustration among investors; while some anticipate a breakout for MSTR, others express concern over its underperformance relative to Bitcoin and other crypto-related stocks. Community chatter highlights debates about dilution, fair value, and whether MSTR can reclaim its past correlation with Bitcoin's price movements, with some suggesting better opportunities elsewhere.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evaxion A/S (EVAX) said on Thursday that it has out-licensed its vaccine candidate EVX-B3 to Merck (MRK), sending shares of the company rallying 42% in the pre-market session.Evaxion will receive a cash payment of $7.5 million in addition to future milestone payments of up to $592 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://evaxion.ai/investors/press-releases/?press_release_id=10586">said</a>. It will also be eligible for royalties on net sales.The cash payment will extend Evaxion’s cash runway to the first half of 2027, it said. Cash at hand will be invested in operating and developing the business, it added.The out-licensing is part of the option and license agreement between the two companies in September 2024. Merck will now be wholly responsible for the further development of the EVX-B3 vaccine, which is in preclinical development.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EVAX">EVAX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.EVX-B3 was discovered and developed in a collaboration between Evaxion and Merck. It aims to address a serious global medical issue for which no vaccines are currently available, Evaxion said, without naming the condition.Merck retains an option in a second vaccine candidate called EVX-B2. It is a preclinical vaccine candidate against Gonorrhea, and a decision on potential licensing is expected in the first half of 2026. Were Merck to exercise the option, Evaxion will receive a cash payment of $2.5 million and will be eligible for milestone payments of up $592 million in addition to royalties on sales.EVAX stock is down 22% this year and approximately 77% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.

Equity

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.


Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Upgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX - Free Report) from a neutral rating to a buy rating in a report published on Tuesday, Marketbeat.com reports. The firm...

Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...

Evaxion Biotech Announces Upcoming Annual Meeting

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...

Evaxion Announces Business Update and Full Year 2023 Financial Results

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology  Platform

The proprietary AI-Immunology platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology outcompetes...

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Biotech A/S Expected to Post FY2023 Earnings of ($6.90) Per Share (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX  Free Report)  Equities researchers at HC Wainwright issued their FY2023 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued...

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Evaxion A/S - ADR

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$5.72
Prev Close	$6.95
Open	$7.03
Dividend Yield	0.00%
50-Day Moving Average	$3.21
Beta	0.54
Avg. Volume	3.88M
PE Ratio	-1.17

52-Week High	$15.50
52-Week Low	$1.20
Market Capitalization	$43.9M
EPS (Annual)	-$9.83
Price to Book	7.05
Revenue Per Employee	$72,579.04
Enterprise Value/EBITDA	N/A

EVAX Evaxion Biotech

Feed

News

Sentiment

Fundamentals

Info

Latest EVAX News